Next Article in Journal
Delivery of Iron Oxide Nanoparticles into Primordial Germ Cells in Sturgeon
Next Article in Special Issue
For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors
Previous Article in Journal
Highly Glycolytic Immortalized Human Dermal Microvascular Endothelial Cells are Able to Grow in Glucose-Starved Conditions
Previous Article in Special Issue
Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations
Open AccessReview

Perspective: Potential Impact and Therapeutic Implications of Oncogenic PI3K Activation on Chromosomal Instability

1
UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK
2
Centre for Cardiovascular Sciences, Queens Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
*
Authors to whom correspondence should be addressed.
Biomolecules 2019, 9(8), 331; https://doi.org/10.3390/biom9080331
Received: 21 July 2019 / Revised: 30 July 2019 / Accepted: 31 July 2019 / Published: 1 August 2019
(This article belongs to the Special Issue Phosphoinositide 3-kinase, a Field in Transition)
Genetic activation of the class I PI3K pathway is very common in cancer. This mostly results from oncogenic mutations in PIK3CA, the gene encoding the ubiquitously expressed PI3Kα catalytic subunit, or from inactivation of the PTEN tumour suppressor, a lipid phosphatase that opposes class I PI3K signalling. The clinical impact of PI3K inhibitors in solid tumours, aimed at dampening cancer-cell-intrinsic PI3K activity, has thus far been limited. Challenges include poor drug tolerance, incomplete pathway inhibition and pre-existing or inhibitor-induced resistance. The principle of pharmacologically targeting cancer-cell-intrinsic PI3K activity also assumes that all cancer-promoting effects of PI3K activation are reversible, which might not be the case. Emerging evidence suggests that genetic PI3K pathway activation can induce and/or allow cells to tolerate chromosomal instability, which—even if occurring in a low fraction of the cell population—might help to facilitate and/or drive tumour evolution. While it is clear that such genomic events cannot be reverted pharmacologically, a role for PI3K in the regulation of chromosomal instability could be exploited by using PI3K pathway inhibitors to prevent those genomic events from happening and/or reduce the pace at which they are occurring, thereby dampening cancer development or progression. Such an impact might be most effective in tumours with clonal PI3K activation and achievable at lower drug doses than the maximum-tolerated doses of PI3K inhibitors currently used in the clinic. View Full-Text
Keywords: PI 3-kinase; chromosomal instability; PI3K inhibitor; cancer; tumour evolution; centrosome PI 3-kinase; chromosomal instability; PI3K inhibitor; cancer; tumour evolution; centrosome
Show Figures

Figure 1

MDPI and ACS Style

Vanhaesebroeck, B.; Bilanges, B.; Madsen, R.R.; Dale, K.L.; Lau, E.; Vladimirou, E. Perspective: Potential Impact and Therapeutic Implications of Oncogenic PI3K Activation on Chromosomal Instability. Biomolecules 2019, 9, 331.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop